Sign inCreate account

Report workspace tools

NCT06208033UNKNOWNanonymous

A Single-arm, Sequential Study Assessing the Efficacy and Safety of SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) : First-line Treatment or Failed From First-line Immune Checkpoint Inhibitor Treatment.

Sponsor

Source record

Fujian Cancer Hospital

Phase

Source record

EARLY_PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

SMET12, SMET12, SMET12

Indication / condition

AI-normalized

EGFR Positive Non-small Cell Lung Cancer

Intervention

Source record

SMET12, SMET12, SMET12

Source & freshness

Source record

NCT ID

NCT06208033

Original source

ClinicalTrials.gov

Source last updated

Jan 17, 2024

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06208033

Title

A Single-arm, Sequential Study Assessing the Efficacy and Safety of SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) : First-line Treatment or Failed From First-line Immune Checkpoint Inhibitor Treatment.

Sponsor

Fujian Cancer Hospital

Status

UNKNOWN

Phase

EARLY_PHASE1

Condition raw

EGFR Positive Non-small Cell Lung Cancer

Condition normalized

EGFR Positive Non-small Cell Lung Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

SMET12, SMET12, SMET12

Target normalized

SMET12, SMET12, SMET12

Interventions

SMET12, SMET12, SMET12

Public preview

Source record

This is a single-arm, sequential study assessing the efficacy and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced non-small cell lung cancer (NSCLC) : first-line treatment or failed from first-line immune checkpoint inhibitor treatment.The primary objective is to evaluate the anti-tumor activity and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced NSCLC.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Single-arm, Sequential Study Assessing the Efficacy and Safety of SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) : First-line Treatment or Failed From First-line Immune Checkpoint Inhibitor Treatment.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06208033

Status

UNKNOWN

Phase

EARLY_PHASE1

Sponsor

Fujian Cancer Hospital

Executive brief

Investment-Ready Snapshot

This is a single-arm, sequential study assessing the efficacy and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced non-small cell lung cancer (NSCLC) : first-line treatment or failed from first-line immune checkpoint inhibitor treatment.The primary objective is to evaluate the anti-tumor activity and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced NSCLC.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 17, 2024
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06208033

Indication

EGFR Positive Non-small Cell Lung Cancer

Modality

small molecule

Target

SMET12, SMET12, SMET12

Intervention

SMET12, SMET12, SMET12

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.